Therapeutic Applications of Human Heme Oxygenase Gene Transfer and Gene Therapy

2003 ◽  
Vol 9 (30) ◽  
pp. 2513-2524 ◽  
Author(s):  
Nader Abraham
Keyword(s):  
Gene Therapy ◽  
Gene Transfer ◽  
Heme Oxygenase ◽  
Therapeutic Applications

Heme Oxygenase -1 Gene Therapy: Recent Advances and Therapeutic Applications

2007 ◽  
Vol 7 (2) ◽  
pp. 89-108 ◽  
Author(s):  
Nader Abraham ◽  
Amit Asija ◽  
George Drummond ◽  
Stephen Peterson
Keyword(s):  
Gene Therapy ◽  
Heme Oxygenase ◽  
Heme Oxygenase 1 ◽  
Therapeutic Applications ◽  
Recent Advances

Gene Therapy in Fanconi Anemia: A Matter of Time, Safety and Gene Transfer Tool Efficiency

2017 ◽  
Vol 16 (5) ◽  
pp. 297-308 ◽  
Author(s):  
Els Verhoeyen ◽  
Francisco Roman-Rodriguez ◽  
Francois-Loic Cosset ◽  
Camille Levy ◽  
Paula Rio
Keyword(s):  
Gene Therapy ◽  
Gene Transfer ◽  
Fanconi Anemia

scholarly journals Efficient and Selective Gene Transfer into Primary Human Brain Tumors by Using Single-Chain Antibody-Targeted Adenoviral Vectors with Native Tropism Abolished

2002 ◽  
Vol 76 (6) ◽  
pp. 2753-2762 ◽  
Author(s):  
Victor W. van Beusechem ◽  
Jacques Grill ◽  
D. C. Jeroen Mastenbroek ◽  
Thomas J. Wickham ◽  
Peter W. Roelvink ◽  
...  
Keyword(s):  
Gene Therapy ◽  
Gene Transfer ◽  
Brain Tumors ◽  
Human Brain ◽  
Cancer Gene Therapy ◽  
Adenoviral Vectors ◽  
Receptor Expression ◽  
Normal Brain ◽  
Cancer Gene ◽  
Single Chain

ABSTRACT The application of adenoviral vectors in cancer gene therapy is hampered by low receptor expression on tumor cells and high receptor expression on normal epithelial cells. Targeting adenoviral vectors toward tumor cells may improve cancer gene therapy procedures by providing augmented tumor transduction and decreased toxicity to normal tissues. Targeting requires both the complete abolition of native tropism and the addition of a new specific binding ligand onto the viral capsid. Here we accomplished this by using doubly ablated adenoviral vectors, lacking coxsackievirus-adenovirus receptor and αv integrin binding capacities, together with bispecific single-chain antibodies targeted toward human epidermal growth factor receptor (EGFR) or the epithelial cell adhesion molecule. These vectors efficiently and selectively targeted both alternative receptors on the surface of human cancer cells. Targeted doubly ablated adenoviral vectors were also very efficient and specific with primary human tumor specimens. With primary glioma cell cultures, EGFR targeting augmented the median gene transfer efficiency of doubly ablated adenoviral vectors 123-fold. Moreover, EGFR-targeted doubly ablated vectors were selective for human brain tumors versus the surrounding normal brain tissue. They transduced organotypic glioma and meningioma spheroids with efficiencies similar to those of native adenoviral vectors, while exhibiting greater-than-10-fold-reduced background levels on normal brain explants from the same patients. As a result, EGFR-targeted doubly ablated adenoviral vectors had a 5- to 38-fold-improved tumor-to-normal brain targeting index compared to native vectors. Hence, single-chain targeted doubly ablated adenoviral vectors are promising tools for cancer gene therapy. They should provide an improved therapeutic index with efficient tumor transduction and effective protection of normal tissue.

scholarly journals Light-induced adenovirus gene transfer, an efficient and specific gene delivery technology for cancer gene therapy

2002 ◽  
Vol 9 (4) ◽  
pp. 365-371 ◽  
Author(s):  
Anders Høgset ◽  
Birgit Øvstebø Engesæter ◽  
Lina Prasmickaite ◽  
Kristian Berg ◽  
Øystein Fodstad ◽  
...  
Keyword(s):  
Gene Therapy ◽  
Gene Transfer ◽  
Gene Delivery ◽  
Cancer Gene Therapy ◽  
Specific Gene ◽  
Cancer Gene ◽  
Delivery Technology

scholarly journals Gene transfer to human joints: Progress toward a gene therapy of arthritis

2005 ◽  
Vol 102 (24) ◽  
pp. 8698-8703 ◽  
Author(s):  
C. H. Evans ◽  
P. D. Robbins ◽  
S. C. Ghivizzani ◽  
M. C. Wasko ◽  
M. M. Tomaino ◽  
...  
Keyword(s):  
Gene Therapy ◽  
Gene Transfer ◽  
Human Joints

Products of heme oxygenase and their potential therapeutic applications

2006 ◽  
Vol 290 (3) ◽  
pp. F563-F571 ◽  
Author(s):  
Kristin A. Kirkby ◽  
Christopher A. Adin
Keyword(s):  
Heme Oxygenase ◽  
Heme Oxygenase 1 ◽  
Inexpensive Method ◽  
Waste Products ◽  
Biliverdin Reductase ◽  
Therapeutic Applications ◽  
Beneficial Effects ◽  
Tissue Protection ◽  
Organ Systems ◽  
Dose Dependent

Heme oxygenase 1 (HO-1) is induced in response to cellular stress and is responsible for converting the prooxidant heme molecule into equimolar quantities of biliverdin (BV), carbon monoxide (CO), and iron. BV is then converted to bilirubin (BR) by the enzyme biliverdin reductase. Experimental evidence suggests that induction of the HO system is an important endogenous mechanism for cytoprotection and that the downstream products of heme degradation, CO, BR, and BV, may mediate these powerful beneficial effects. These molecules, which were once considered to be toxic metabolic waste products, have recently been shown to have dose-dependent vasodilatory, antioxidant, and anti-inflammatory properties that are particularly desirable for tissue protection during organ transplantation. In fact, recent work has demonstrated that administration of exogenous CO, BR, or BV may offer a simple, inexpensive method to substitute for the cytoprotective effects of HO-1 in a variety of clinically applicable models. This review will attempt to summarize the relevant biochemical and cytoprotective properties of CO, BR, and BV, and will discuss emerging studies involving the therapeutic applications of these molecules in the kidney and other organ systems.

Sign in / Sign up

Export Citation Format

Share Document